DDInter1296 DDInter1658
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nintedanib may lead to a major life threatening interaction when taken with Lomitapide
Nintedanib may lead to a major life threatening interaction when taken with Lumacaftor